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Estrogen (E) and testosterone (T) are important in the sexually dimorphic pattern of blood pressure (BP) development. The
goal was to examine the eﬀects of endogenous E and exogenous T in the development of hypertension in female spontaneously
hypertensive rats (SHR) on a high sodium diet. Female SHR (N = 27, 5-week) were divided into four groups: (1) control (n = 8),
(2) ovariectomized (OVX, n = 26), (3) testosterone implants with intact ovaries (T, n = 6), and (4) ovariectomized + testosterone
implants (OVX+T, n = 7). T was given immediately after OVX and replaced every two weeks and they were fed a 3% NaCl diet.
BP was measured weekly and plasma norepinephrine (NE) analyzed by HPLC. OVX+T females exhibited the greatest elevation
in BP (190 ± 4.0mmHg) compared to controls at 15 weeks of age (140 ± 3.4mmHg, P<. 001) and a pattern of hypertension
development similar to that of male SHR. Females with T treatment showed evidence of glomerulosclerosis. In conclusion, T
accelerated the development of hypertension similar to the BP pattern observed in males; the presence of ovaries attenuated the T
induced increase in BP; T increased renal sodium reabsorption, and T increased glomerulosclerosis.
1.Introduction
A sexual dimorphism in blood pressure (BP) exists in most
mammalian populations with males having higher and more
rapid elevation of BP than females [1, 2]. In most strains
of rats used to study, BP this sex diﬀerence exists, such
as in normotensive Sprague-Dawley rats [3], in Dahl salt-
susceptible and salt-resistant rats [4], and in spontaneously
hypertensive rats (SHRs) [5]. Also, there are gender diﬀer-
encesinBPdevelopmentinhuman hypertension, with males
having higher BP at an earlier age than females. However, the
prevalence of hypertension is actually higher in age-adjusted
females, and the current rise in hypertension prevalence is
primarily driven by women [6]. The triggers for gene and
physiological system activation regulating BP, like the renin
angiotensin system, the sympathetic nervous system and
oxidative stress pathways are most likely regulated diﬀerently
in females than in males [7].
Both androgens and estrogensare being used more wide-
ly,andstudies needtobedonetoproperlyassess beneﬁtsand
risks on the cardiovascular and renal systems. Androgen use
is occurring in women as a treatment for sexual dysfunction
and bone mass loss and to enhance cognition in aging [8].
However, more studies need to explore androgen dosages
in females across the life span since requirements and
physiological eﬀects change [9, 10]. One of the potential
risks for long-term androgen use in women is associated
with impaired vascular reactivity which was found in genetic
females (transgender population) [11]. Although there have
not been many studies of chronic androgen use in females,
Van Kesteren et al. [12] showed that in 293 transgender cases
there were no increased risks of heart disease compared to
the general population, butphysiological measures and renal
disorders were not examined. Nonhuman primate studies
show that ovariectomized females treated with androgens
for 8 months had increased coronary artery plaque size
compared to controls, and this eﬀect was not explained by
lipid changes [13]. To further characterize the relationship
between sex steroids and BP, gonadectomy and hormone
replacement experiments have been done. Castration lowers2 Advances in Pharmacological Sciences
BP in males, and T replacement increases BP and renal
pathology [14–16]. Not only T, but also the presence of
androgen receptors inﬂuence the development of hyperten-
sion. Our laboratory showed that hybrid SHR (the male
oﬀspring of King Holtzman females carrying the testicular
feminized mutation bred with an SHR male) without
functional androgen receptors had signiﬁcantly reduced
BP compared to those with functional androgen receptors
[17].
Althoughmost oftheliteraturesupportsthe conceptthat
T potentiates while E attenuates the development of hyper-
tension, controversy exists regarding the mechanisms played
in BP regulation by both steroids [18]. Also, our laboratory
and others have explored the eﬀect of varying sodium diets
on the development of high BP in SHR and WKY animals
[19]. Our results and others have focused primarily on the
males and only a few studies have examined the eﬀects of E
and T in females on a high sodium diet. The present study
tested the hypothesis that exogenous T will increase BP in
SHR females with a male pattern of BP on a high sodium
diet which will result in reduced sodium excretion and renal
pathology.
2.Materialsand Methods
2.1. Animals, Diet, and Treatments. Female SHR (N = 27)
were obtained from Harlan Sprague Dawley (Indianapolis,
Indiana) at four weeks of age. At ﬁve weeks of age, animals
were housed two per cage (polyethylene animal cages, 50 ×
38 × 20cm) with steel lids and bedding changed weekly
( P .J .M u r p h y ,F o r e s tP r o d u c t s ,M o n t v i l l e ,N J ) .T h e yw e r e
maintained at a constant temperature (25–27◦C) and 40–
50% humidity. Lighting was controlled by an automatic
timer which allowed illumination from 6:00 AM to 6:00
PM daily. All rats were fed a high sodium rat chow (3%
NaCl) made from ﬁne powdered rodent blox (Laboratory
RodentDiet 48904-F4, Harlad Teklad, Madison, Wisconsin).
The purpose of the high sodium diet was to compare
SHR female BP and pathology responses to those of SHR
males previously studied on the same high sodium diet
[19]. Food and tap water were available ad libitum.A l l
animals were treated humanely following NIH guidelines,
and all protocols were approved by The University of Akron
IACUC.
The rats were randomly divided into four groups at
ﬁve weeks of age and received the following treatments:
sham operation with blank implants = controls (C, n =
8), ovariectomized (OVX, n = 6), testosterone implant (T,
n = 6), and ovariectomized and T implantation (OVX +
T, n = 7). The implants were changed every 2 weeks under
anesthesia (Brevital Sodium 50mg/Kg, i.p., Eli Lilly and Co.
Indianapolis, IN). The OVX groups were ovariectomized
before they are considered adults which is about 8 weeks of
age. The sham rats given T may have had their estrous cycle
i n ﬂ u e n c e d ,b u ts m e a r sf o rt h ee s t r u ss t a g ew e r en o tt a k e n .
W h e nB Pw a se x a m i n e da c r o s st h ee s t r o u sc y c l e ,i td i dn o t
changebased onunpublisheddatafromanotherstudy inour
lab.
Implants were made of silastic medical grade tubing
(1.19mm, i.d., 16mm, length; Dow Corp. Midland, MI),
packed with testosterone propionate (T, 20mg/capsule,
Sigma, St. Louis, MO) and sealed with silastic adhesive type
A as previously described (Dow Corning Corp. Midland,
MI) [17]. This length of implant delivered a T dose that
was similar to control levels of T and used previously in
BP and androgen receptor experiments [17]. Implants were
i n c u b a t e di na na l b u m i nb u ﬀered primer solution at 5◦Cf o r
12 hours and soaked in 75% ethanol alcohol for 2 hours
before insertion. Sham implants were given to the OVX
group.
2.2. Blood Pressure and Kidney Histology. BP was measured
weekly, from 6 to 15 weeks of age, by the tail-cuﬀ method
using a sphygmomanometer and physiograph recorder
(Narco, Bio-System, Houston, TX) [20]. Rats were individ-
ually placed in a preheated chamber (39◦C) for 15 minutes.
Rat restrainers were used to keep animals in position
while their BP was taken. The mean of ﬁve successive BP
measurements was used as the average BP for each rat.
Body weight was determined weekly on the same day as
the BP was measured. All animals were sacriﬁced after 15
weeks and kidneys weighed and processed (Tissue-Tek V.I.P.
1000 processor) for histology and embedded in paraﬃn
[16]. Sections were cut at 5um, placed on glass slides, and
stained with hematoxylin and eosin. A qualitative scale of 0,
I-II, and III-IV was used to score glomeruli, with 0 being
normal having a glomerulus that ﬁlled Bowman’s capsule,
I-II representing moderate glomerulosclerosis where the
glomerulus had shrunk to 20–40%, and III-IV representing
severe glomerulosclerosis where the glomerulus had shrunk
to 40–60%, [16]. Scoring of 100 glomeruli per kidney was
done by three individuals blinded to the treatments and the
scores averaged.
2.3. Plasma Norepinephrine and Sodium Measures. All blood
samples were collected on ice and centrifuged (5000×G,
10min). Plasma was obtained and stored at −70◦Cf o r
further analysis. Plasma NE was measured at 15 weeks of
age by HPLC with electrochemical detection as previously
described [21]. Brieﬂy, animals were taken in their home
cage to a surgical suite and anesthetized with Brevital and
a retro-orbital puncture performed. About 2.5mL of blood
was collected in less than a minute. The plasma level of NE
is high compared to collection by other techniques perhaps
because of the movement of the cages to a new room,
application of an anesthetic, and the fact that animals are
on a high sodium diet, which elevates plasma NE [22]. We
get plasma NE values of about 1500pg/mL from male SHR
in a colony environment compared to 2500–3000pg/mL in
these experiments[21].To collecturine forsodiumexcretion
analysis, animals were put into metabolic cages for 24hr at 8
and 15 weeks. Urinary sodium was measured using a sodium
sensitive electrode (Fisher, Pittsburgh, PA).
2.4. Statistical Analysis. Diﬀerences in BP, sodium excretion,
pathology scores, kidney weight, and T levels were measuredAdvances in Pharmacological Sciences 3
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Figure 1: Systolic blood pressure of female SHR by treatment
and time (means ± SEM). Two-way repeated measures ANOVA:
treatment-F = 19.6, df = 3, P<. 001, age-F = 14.7, df = 9,
P<. 001, interaction-F = 2.3, df = 27, P<. 001. Solid circles:
controls (n = 8), solid triangles: ovarectomy-OVX (n = 6), open
circles: testosterone treated-T (n = 6), open triangles: ovarectomy
and testosterone treatment-OVX+T (n = 7).
at diﬀerent time intervals, and the statistical comparisons
were analyzed between the experimental and control groups.
Two-way ANOVA with repeated measures followed by
appropriate t-tests (Kruskal-Wallis) was used for the com-
parison between control and treatment groups and for the
renal pathology one-way ANOVA and follow-up Dunn’s
method pair-wise comparisons (SigmaStat,Jandel Scientiﬁc,
Corte Madera, CA). All data were presented as mean ± SEM.
The signiﬁcance was set at the level of P<. 05.
3.Results
BP change over time by group is shown in Figure 1 (two-
way ANOVA: treatment: F = 19.6, df = 3, P<. 001,
age: F = 14.7, df = 9, P<. 001, interaction: F = 2.3,
df = 27, P<. 001). BP was highest at 15 weeks of age in
the OVX+T group (190 ± 4mmHg) compared to controls
(138 ± 3mmHg, P<. 001). The T group also had elevated
BP compared to controls at 15 weeks (156 ± 5mmHg and
138 ± 3mmHg, resp., P<. 05). The BP of the OVX
group was not signiﬁcantly diﬀerent than the controls at
15 weeks (146 ± 5mmHg compared to 138 ± 3mmHg).
Figure 2 shows that sodium excretion in all treated groups
was signiﬁcantly reduced compared to controls at both 8 and
15 weeks ranging 50–84%. There was less overall sodium
excretion with time, and at 15 weeks the OVX+T group had
an84%reduction.Two-way ANOVAwithrepeated measures
showed a signiﬁcant treatment eﬀect (F = 9.1, P<. 001) but
not an age eﬀect (F = 3.1, not signiﬁcant), and there was no
signiﬁcant interaction.
With regard to plasma NE, there were both a signiﬁcant
treatment and age eﬀect (treatment: F = 6.29, P<. 01; age:
F = 101,P<. 001;no interaction signiﬁcance, Figure 3). The
treatment eﬀect was consistent across time in that OVX+T
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Figure 2: Urinary sodium excretion (24hr) by age and treatment
(means ± SEM). Two-way repeated measures ANOVA: treatment-
F = 9.1, df = 3, P<. 001, age-F = 3.1, df = 9, P<. 05, interaction
not signiﬁcant. Open bars: controls (C, n = 8), solid black bars:
ovarectomy (OVX, n = 6), gray bars: testosterone treated (T, n =
6), striped bars: ovarectomy and testosterone treatment (OVX+T,
n = 7) (∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 compared to control).
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Figure 3: Plasma norepinephrine at the end of the experiment by
treatment group (means ± S.E.M.). Open bars: controls, n = 8,
solid black bars: ovarectomy (OVX, n = 6), gray bars: testosterone
treated (T, n = 6 ) ,s t r i p e db a r s :o v a r e c t o m ya n dt e s t o s t e r o n e
treatment (OVX+T, n = 7). One-way ANOVA: H = 9.6, df = 3,
P<. 05, ∗P<. 05 compared to controls, ++P<. 01 compared to
testosterone treatment.
had increased NE at 7 weeks (P<. 05) and at 14 weeks (P<
.05) compared to respective controls. At 7 weeks, there was a
signiﬁcant decrease in NE in the OVX group which was not
observed at 14 weeks.
Figure 4 is a representative micrograph of a kidney from
each of the four treatment groups. The glomeruli were
degenerating creating a greater distance between them and
Bowman’s capsule with scarring of the glomerulus.
Table 1 shows the scoring of the glomeruli by treatment
group.In all groups,there wassome glomerularchange most
probably due to the high sodium diet. One-way ANOVA
was signiﬁcant between treatments (H = 63.4, df = 11,4 Advances in Pharmacological Sciences
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Figure 4: Representative renal micrographs stained with hematoxylin and eosin by treatment groups (controls, OVX: ovarectomy, T: testo-
sterone, OVX+T: ovarectomy and testosterone) showing glomerulosclerosis(arrows point to glomeruli, magniﬁcation = 100x).
Table 1: Glomerular scores by treatment and severity.
Group 0 I-II III-IV
Control (n = 8) 1.9 ± 0.6 96.4 ± 0.8 1.7 ± 0.2
OVX (n = 6) 0.6 ± 0.08 96.4 ± 0.9 3.0 ± 1.0
Testosterone (n = 6) 1.0 ± 0.4 89.3∗± 2.1 9.7∗± 2.4
OVX +T (n = 7) 1.4 ± 1.0 83.0∗∗± 2.8 15.6∗∗± 3.4
(means ± S.E.M., ∗P<. 05, ∗∗P<. 01 compared to controls, OVX:
ovarectomy, OVX+T: ovarectomy and testosterone treatment, 0: normal
glomerulus, I-II: moderate glomerulosclerosis, III-IV: severe glomeruloscle-
rosis).
P<. 001).ThecontrolsandOVXgroupsshowedthatmostof
the glomeruli were in the I-II category (96%) and only 1.7–
3% in the III-IV category. However, there was a signiﬁcant
increase in structural change in the T and OVX+T groups
with 9.7–15.6% in category III-IV and 89–83%, respectively,
in category I-II.
4.Discussion
4.1. Blood Pressure. In the present study, we demonstrated
that E removal (ovarectomy) combined with T (OVX+T)
treatmentsigniﬁcantlyelevatedBPinfemaleSHRscompared
to controls, OVX, or T groups all on a high sodium diet
(3%). This represents a male pattern of BP rise with time.
For instance, in a previous study we showed that BP rose in
SHR males between 5 and 15 weeks from 138 to 190mmHg
orabout5mmHg/week[23].TheSHRfemalesinthepresent
study in the OVX+T group rose 145–190mmHg in 9 weeks
or about 5mmHg/week. The BP pattern of the OVX+T
group rose weekly until the last 3 weeks and then reached
a plateau. The control and OVX groups reached a peak
BP about week 11 and then leveled oﬀ,w h e r e a st h eT
group had a decrease in BP after week 11 and a decline
from 170 to 150mmHg at week 14. The drop in BP in
the T group from week 11 to 12 and 11 to 13 was not
signiﬁcant, but the diﬀerence between week 11 and week 14
was signiﬁcant (P<. 05). The explanation for this decrease
is not known, but the T implant was not the problem.
Every two weeks, the implants were replaced and there was
always T remaining in the implant. Also there were no
changes in environmental conditions that could explain the
fall in the BP. Possibly, there was a compensation by E to
reduce the BP by vasodilation since this group still had
ovarian function. Using a normal sodium diet, Chen and
Meng [24] found similar results regarding the inﬂuence ofAdvances in Pharmacological Sciences 5
T on the development of hypertension in both male and
female SHR during 4–20 weeks of age. In order to explain
potential mechanisms for the BP eﬀect, the inﬂuence of the
high sodium diet should be examined. Caplea et al. [22]
showed that a high sodium diet increased plasma NE by
71% compared to animals on a control sodium diet and
treatment with clonidine normalized the plasma NE rise.
Since all of the groups were on the same high sodium
diet this variable cannot explain the group diﬀerences. The
plasma level of NE for all groups is high compared to NE
levels collected from conscious SHR rats due to several
factors: the movement of the cages to a new room could
activate the SNS and release more NE; application of an
anesthetic can also activate the SNS and the animals were
on a high sodium diet which elevates plasma NE [22]. We
get plasma NE values of about 1500pg/mL from male SHR
in a colony environment using this technique compared to
2500–3000pg/mL in these experiments with females [21].
Also we have shown that a high sodium diet alone does
not increase BP in SHR, if the animals are not socially
stressed by interacting in a colony environment (open ﬁeld
caging with males and females interacting) [22, 25]. A
colony environment combined with a high sodium diet
did signiﬁcantly raise telemetered BP in both normotensive
WKY and hybrid SHR males but not without the colony
stimulation [22]. This brings us to the involvement of T
in the BP eﬀect. In the above study by Caplea et al. [22]
when the colony males (socially interacting in an open ﬁeld
environment) were given an androgen receptor antagonist
(ﬂutamide) the nocturnal rise in BP was eliminated in
spite of the high sodium diet suggesting that T when
bound to the androgen receptor produced the elevated
BP. We know that castration lowers BP in males and T
replacement increases BP [14–16]. Not only T, but also
the presence of androgen receptors are necessary for the
development of hypertension. Hybrid SHR males (the male
oﬀspring of King Holtzman females carrying the testicular
feminized mutation bred with an SHR male) without
functional androgen receptors had signiﬁcantly reduced
BP compared to those with functional androgen receptors
[17].
4.2.Testosterone-Norepinephrine Interaction. SoifplasmaNE
is elevated by T and T can inﬂuence BP, is there evidence
of a T-NE interaction? In SHR males, Jones et al. showed
that T enhanced the renal fractional release of NE (>100%
compared to castrates) from the kidney [26]. Kumai et al.
established that androgens administered to castrated SHR
males raised tyrosine hydroxylase in the adrenal medulla
[27] and in the aorta and mesenteric arteries [28]l e a d i n gt o
increased NE and elevated BP. T can elevate BP by increasing
theresponsiveness ofresistance vesselstosympathetic stimu-
lation through several mechanisms. For instance, T increases
α-adrenergic receptors in smooth muscle cells [29], and T
increases the release of the vasoconstrictor norepinephrine
(NE) [30]. Our laboratory has veriﬁed this result and found
that T increased renal NE content and fractional release of
NE in response to renal nerve stimulation [26]. This may be
an important mechanism which enhances the reabsorption
of sodium in the kidney [31]. T has been implicated in
reduced renal sodium excretion and may involve blunting
of the pressure-natriuresis relationship [31].Otherinvestiga-
tors have demonstrated that T causes a delayed inactivation
of NE via inhibition of the NE up-take mechanism [32], and
this action would increase the availability of NE to bind to
alpha receptors on blood vessels and promote vasoconstric-
tion.
4.3. Estrogen. Ea l s oh a sar o l ei nBPr e g u l a ti o ni nth ef e m a l e .
E relaxes blood vessels by increasing the synthesis [33]a n d
release [34] of nitric oxide, a potent endothelial vasodilator
[35]. Moreover, E can relax coronary arteries by stimulating
the gating of the large-conductance Ca++ and voltage-
activated K+ channels in smooth muscle, which retards the
contractility of this tissue [36]. Our data suggest that E had
some protective eﬀect on BP since T did raise BP as much
if the ovaries were present compared to when they were
absent. E may also be protective against hypertension by
amplifying the vasodilator contributions of angiotensin (1–
7), while reducing the formation and vasoconstrictor actions
of angiotensin II [37] .S o m eo ft h ep r o t e c t i v ee ﬀects of E
may be negated by T in that T administered to macrophages
decreased nitrite release by decreasing inducible nitric oxide
synthase which could increase platelet aggregation and
thrombosis risk [38].
Based on the results of this study, we could not exclude
the eﬀects of ovarian hormones other than E, such as pro-
gesterone, on BP in the two groups with ovaries. However,
the day that BP measurements were taken was random
with regard to the ovarian cycle which should minimize
interference on BP due to progesterone. It is important to
note that with the OVX procedure,not only isE lost, butalso
other ovarian hormones are removed which could have an
impact on BP and renal function.
4.4. Sodium Reabsorption. With regards to sodium reab-
sorption, the data show that both E and T increased renal
sodium reabsorption. The OVX group does not have E but it
does have some adrenal gland produced T; the T group has
both E and T present, and the OVX+T group has mostly T
present. In all these groups, sodium reabsorption increased.
Istheredatasuggestingthat thesesteroidscan inﬂuencerenal
sodium processing? Castration increases sodium excretion
and T replacement restores sodium excretion to control
levels in both WKY and SHR/y males [39]. Also defective
androgen receptors in the kidney and antiandrogens like
ﬂutamide increased Na excretion [39, 40]. In six-month-
old female Sprague-Dawley rats, OVX resulted in decreased
sodium excretion (>50%) compared to controls suggesting
an E eﬀect [41]. Potential mechanisms for the E eﬀects
on sodium excretion may be through both AT1 and AT2
receptors and the renal epithelial sodium channel (ENaC).
In WKY females, AT1 and AT2 receptor expression was E
dependent [42]. In Wistar rats, ENaC subunit expression
was higher in females than males, and the diﬀerences were
abolished by OVX and restored by E [43]. Since ENaC is
the primary route for sodium absorption in the mammalian6 Advances in Pharmacological Sciences
distal tubule, it is probable that it plays an important role in
sodium handling and is regulated by E.
4.5. Renal Histology. With regard to renal injury, one poten-
tial mechanism to explain the T eﬀe c to nB Pa n dt h ek i d n e y
is the interaction between T and the sympathetic nervous
system (SNS). We have reported that neonatal sympathec-
tomy reduced glomerulosclerosis scores in our consomic Y
chromosome strain that has a WKY genetic background
with an SHR Y chromosome [44]. Also we have shown
that females with an SHR autosomal background have a
higher renal NE turnover rate than males of the same strain
[45]. This suggests that the females may have more renal
sympathetic activity but be protected from renal injury
i nt h ep r e s e n c eo fE .H o w e v e r ,w h e nEi sr e m o v e do rT
is added in the presence of a high sodium diet, there is
further increased SNS activity and acceleration of renal
injury. In anothermodel using SpragueDawley rats, elevated
SNS activity (induced by phenylephrine infusion) produced
salt-dependent hypertension (measured by telemetry) after
cessation of the infusion and renal injury [46]. The injury
wasnotprimarily glomerularbuttubular-interstitial.NEcan
cause glomerular damage by producing renal ischemia and
glomerular collapse and damage can be caused by very high
glomerular hydrostatic pressure generated by elevated NE
[47].
The combination of T and NE impacting the kidney may
be more important for initiating renal injury than elevated
BP. A large body of evidence supports the concept that renal
dysfunction occurs ﬁrst, followed by the development of
hypertension [48]. Reckelhoﬀ and Granger have postulated
that a combination of increased T and angiotensin II
increased renal Na reabsorption and elevated glomerular
capillary pressure produce glomerular injury [40]. High BP
does not appear to play the only role in the development
of renal pathology since ACE inhibition controlled BP
eﬀectively in SHR but only postponed the onset of kidney
disease [49]. Indeed, in male SHR when we lowered the BP
with hydralazine but did not alter T, we still observed renal
pathology [16]. In SHR male controls, the highest glomeru-
lar damage resulted after 10 weeks when BP approached
220mmHg. Removal of T signiﬁcantly reduced BP and
renal damage. In addition, removal of T combined with
hydralazine further reduced glomerular damage but not BP.
When T was added after castration, BP and glomerular
damage increased [16].
Also, normotensive virgin Munich-Wistar females and
males castrated at 10 weeks of age were protected from renal
injury during aging (18–20 months) [50]. Females were
more protected than males which may have been due to a
metalloproteinase protection in females [50]. Similarly, in
normotensive ageing Wistar and Sprague-Dawley rats, cas-
tration of the male prevented the age-related glomeruloscle-
rosis which supports a mechanism that does not necessarily
require high blood pressure in order for glomerulosclerosis
to occur but does require T [51].
In rats, transgenic for both the human renin and angi-
otensinogen genes, hypertension and kidney damage devel-
oped which was largely independent of BP elevation but was
dependent on an androgen component [51]. For instance,
androgen receptor blockade (ﬂutamide) signiﬁcantly atten-
uated the development of hypertension in females and
reduced plasma renin activity and rat renin mRNA in the
kidney [52]. Urinary albumin excretion was blunted, colla-
gen III mRNA was signiﬁcantly decreased, and no histologi-
cal characteristics of end-organ damage were observed in the
kidney after treatment [52]. These results demonstrated that
when the androgen receptor is blocked, there is protection
against hypertension and end-organ damage not only in
male but also in female transgenic rats (TGRmREN27)
[52].
In summary, exogenous T and the absence of ovarian
estrogen increased BP in SHR females producing a male pat-
tern of BP rise which resulted in reduced sodium excretion,
elevated plasma NE and renal pathology. The loss of E alone
did not cause a rise in BP, plasma NE, or renal pathology.
However, the combination of the loss of E and the addition
of T contributed to the elevated BP raised plasma NE and
renal glomerular changes.
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